...
首页> 外文期刊>European journal of clinical nutrition >The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study
【24h】

The influence of probiotic supplementation on gut permeability in patients with metabolic syndrome: An open label, randomized pilot study

机译:补充益生菌对代谢综合征患者肠道通透性的影响:开放标签,随机先导研究

获取原文
获取原文并翻译 | 示例
           

摘要

Background/objectives: Obesity and metabolic disorders are linked to inflammation via gut microbiota and/or gut permeability. Gut-derived endotoxin triggers inflammation leading to metabolic syndrome (MetS) and contributing to oxidative stress. We intended to investigate the effect of Lactobacillus casei Shirota on gut permeability, presence of endotoxin and neutrophil function in MetS.Subjects/methods: Patients with MetS were randomized to receive 3 × 6.5 × 10 9 CFU L. casei Shirota (probiotic group) or not for 3 months. Gut permeability was assessed by a differential sugar absorption method and by determination of diaminooxidase serum levels, endotoxin by an adapted limulus amoebocyte lysate assay, neutrophil function and toll-like receptor (TLR) expression by flow cytometry and ELISA was used to detect lipopolysaccharide- binding protein (LBP) and soluble CD14 (sCD14) levels.Results: Twenty-eight patients and 10 healthy controls were included. Gut permeability was significantly increased in MetS compared with controls but did not differ between patient groups. None of the patients were positive for endotoxin. LBP and sCD14 levels were not significantly different from healthy controls. High-sensitive C-reactive protein and LBP levels slightly but significantly increased after 3 months within the probiotics group. Neutrophil function and TLR expression did not differ from healthy controls or within the patient groups.Conclusions: Gut permeability of MetS patients was increased significantly compared with healthy controls. L. casei Shirota administration in the MetS patients did not have any influence on any parameter tested possibly due to too-short study duration or underdosing of L. casei Shirota.
机译:背景/目的:肥胖和代谢紊乱通过肠道菌群和/或肠道通透性与炎症相关。肠源性内毒素触发炎症,导致代谢综合症(MetS)并导致氧化应激。我们打算调查干酪乳杆菌Shirota对MetS中肠道通透性,内毒素存在和中性粒细胞功能的影响。受试者/方法:MetS患者随机接受3×6.5×10 9 CFU L.casei Shirota(益生菌组)或3个月没有。通过差异糖吸收法和通过测定二氨基氧化酶血清水平,通过适应性变形细胞溶血产物测定法测定内毒素,中性粒细胞功能和通过流式细胞仪测定的Toll样受体(TLR)表达来评估肠道通透性,并使用ELISA检测脂多糖结合结果:包括28位患者和10位健康对照。与对照组相比,MetS的肠道通透性显着提高,但患者组之间无差异。没有患者内毒素阳性。 LBP和sCD14水平与健康对照组无显着差异。益生菌组3个月后,高敏C反应蛋白和LBP水平略有升高,但显着增加。中性粒细胞功能和TLR表达与健康对照组或患者组无差异。结论:与健康对照组相比,MetS患者的肠道通透性显着提高。在MetS患者中施用干酪乳杆菌Shirota对研究的任何参数都没有任何影响,可能是由于研究时间太短或干酪乳杆菌Shirota剂量不足。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号